Downregulation of Fas ligand by shedding

Nature Medicine

Volumn 4, Issue 1, 1998, Pages 31-36

  Tanaka, Masato ^a,b   Itai, Toshimitsu ^a   Adachi, Masashi ^a   Nagata, Shigekazu ^a,b  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b OSAKA BIOSCIENCE INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LIVER CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; T LYMPHOCYTE ACTIVATION;

ANIMALS; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; HUMANS; JURKAT CELLS; MEMBRANE GLYCOPROTEINS; METALLOENDOPEPTIDASES; MICE; MUTAGENESIS, SITE-DIRECTED; POINT MUTATION; RECOMBINANT PROTEINS; SEQUENCE DELETION; T-LYMPHOCYTES; TRANSFECTION;

EID: 0031938030     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0198-031     Document Type: Article

References (45)

1. Nagata, S. Apoptosis by death factor. Cell 88, 355-365 (1997).
2. Tanaka, M., Suda, T., Takahashi, T. & Nagata, S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J. 14, 1129-1135 (1995).
3. Ferez, C. et al. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 63, 251-258 (1990).
4. Pietravalle, F. et al. Human native soluble CD40L is a biologically active trimer, processed inside microsomes. J. Biol. Chem. 271, 5965-5967 (1996).
5. Tanaka, M. et al. Fas ligand in human serum. Nature Med. 2, 31 7-322 (1996).
6. Gearing, A.J. et al. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 370, 555-557 (1994).
7. McGeehan, G.M. et al. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature 370, 558-561 (1994).
8. Mohler, K.M. et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370, 218-220 (1994).
9. Black, R.A. et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 385, 729-733 (1997).
10. Moss, M.L. et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour necrosis factor-α. Nature 385, 733-736 (1997).
11. Nagata, S. & Golstein, P. The Fas death factor. Science 267, 1449-1456 (1995).
12. Arase, H., Arase, N. & Saito, T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J. Exp. Med. 181, 1235-1238 (1995).
13. +-independent T cell-mediated cytotoxicity. J. Exp. Med. 177, 195-200 (1993).
14. French, L.E. et al. Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J. Cell Biol. 133, 335-343 (1996).
15. Leithauser, F. et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor super-family, in normal and neoplastic cells. Lab. Invest. 69, 415-429 (1993).
16. Watanabe-Fukunaga, R. et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J. Immunol. 148, 1274-1279 (1992).
17. Suda, T. et al. Expression of the Fas ligand in cells of T-cell-lineage, J. Immunol. 154, 3806-3813 (1995).
18. Lowin, B., Hahne, M., Mattmann, C. & Tschopp, J. Cytolytic T-cell cytotoxicity is mediated through perform and Fas lytic pathways. Nature 370, 650-652 (1994).
19. Kägi, D. et al. Fas and perforin pathway as major mechanisms of T cell-mediated cytotoxicity. Science 265, 528-530 (1994).
20. Kondo, T., Suda, T., Fukuyama, H., Adachi, M, & Nagata, S. Essential roles of the Fas ligand in the development of hepatitis. Nature Med, 3, 409-413 (1997).
21. Chrvonsky, A.V. et al. The role of Fas in autoimmune diabetes. Cell 89, 17-24 (1997).
22. Giordano, C. et al. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 275, 960-963 (1997).
23. Itoh, N. et al. Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. J. Exp. Med. 186, 613-618 (1997).
24. Tanaka, M., Suda, T., Yatomi, T., Nakamura, N. & Nagata, S. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J. Immunol. 158, 2303-2309 (1997).
25. Takahashi, S. et al. Establishment of apoptosis-inducing monoclonal antibody 2D1 and 2D1-resistant variants of human T cell lines, Eur. J. Immunol. 23, 1935-1941 (1993).
26. Ni, R. et al. Fas-mediated apoptosis in primary cultured mouse hepatocytes. Exp. Cell Res. 215, 332-337 (1994).
27. Takahashi, T. et al. Human Fas ligand; gene structure, chromosomal location and species specificity. Int. Immunol. 6, 1567-1574 (1994).
28. Aggarwal, B.B. et al. Human tumor necrosis factor: Production, purification, and characterization. J. Biol. Chem. 260, 2345-2354 (1985).
29. Graf, D. et al. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur. J. Immunol. 25, 1749-1754 (1995).
30. Wolfsberg, T.G. et al. ADAM, a widely distributed and developmentalty regulated gene family encoding membrane proteins with a disintegrin and metalloprotease domain. Dev. Biol. 169, 378-383 (1995).
31. Yagami, H.T. et al. A metalloprotease-disintegrin participating in myoblast fusion. Nature 377, 652-6 (1995).
32. Pietravalle, F. et al. Cleavage of membrane-bound CD40 ligand is not required for inducing B cell proliferation and differentiation. Eur. J. Immunol. 26, 725-728 (1996).
33. Kischkel, F.C. et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins from a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14, 5579-5588 (1995).
34. Watanabe, N. et al. Continuous internalization of tumor necrosis factor receptors in a human myosarcoma cell line. J. Biol. Chem. 263, 10262-10266 (1988).
35. Medema, J.P. et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 16, 2794-2804 (1997).
36. Grell, M. et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83, 793-802 (1995).
37. Solorzano, C.C. et al. Involvement of 26-kDa cell-associated TNF-alpha in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. J. Immunol. 158, 414-419 (1997).
38. Bellgrau, D. et al. A role for CD95 ligand in preventing graft rejection. Nature 377, 630-632 (1995).
39. Griffith, T.S., Brunner, T., Fletcher, S.M., Green, D.R. St Ferguson, T.A. Fas Itgand-induced apoptosis as a mechanism of immune privilege. Science 270, 1189-1192 (1995).
40. Lau, HT., Yu, M., Fontana, A. & Stoeckert, C.J., Jr. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273, 109-112 (1996).
41. Allison, J., Georgiou, H.M., Strasser, A. & Vaux, D.L. Transgentc expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA 94, 3943-3947 (1997).
42. Seino, K., Kayagaki, N., Okumura, K. & Yagita, H. Antitumor effect of locally produced CD95 ligand. Nature Med. 3, 165-170 (1997).
43. Kang, S.M. et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med. 3, 738-743 (1997).
44. Karp, S.E. et al. In vivo activity of tumor necrosis factor (TNF) mutants: Secretory but not membrane-bound TNF mediates the regression of retroviralty transduced murine tumor. J. Immunol. 149, 2076-2081 (1992).
45. Mizushima, S. & Nagata, S. pEF-BOS: A powerful mammalian expression vector. Nucleic Acids Res. 18, 5322 (1990).